255 related articles for article (PubMed ID: 11052222)
1. Molecular effects of dopamine on striatal-projection pathways.
Gerfen CR
Trends Neurosci; 2000 Oct; 23(10 Suppl):S64-70. PubMed ID: 11052222
[TBL] [Abstract][Full Text] [Related]
2. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase.
Gerfen CR; Miyachi S; Paletzki R; Brown P
J Neurosci; 2002 Jun; 22(12):5042-54. PubMed ID: 12077200
[TBL] [Abstract][Full Text] [Related]
3. Differential perikaryal localization in rats of D1 and D2 dopamine receptors on striatal projection neuron types identified by retrograde labeling.
Deng YP; Lei WL; Reiner A
J Chem Neuroanat; 2006 Dec; 32(2-4):101-16. PubMed ID: 16914290
[TBL] [Abstract][Full Text] [Related]
4. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons.
Surmeier DJ; Ding J; Day M; Wang Z; Shen W
Trends Neurosci; 2007 May; 30(5):228-35. PubMed ID: 17408758
[TBL] [Abstract][Full Text] [Related]
5. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts.
Puschban Z; Scherfler C; Granata R; Laboyrie P; Quinn NP; Jenner P; Poewe W; Wenning GK
Neuroscience; 2000; 95(2):377-88. PubMed ID: 10658617
[TBL] [Abstract][Full Text] [Related]
6. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson's disease.
Gerfen CR
Neuroscientist; 2003 Dec; 9(6):455-62. PubMed ID: 14678578
[TBL] [Abstract][Full Text] [Related]
7. Phasic Dopamine Modifies Sensory-Driven Output of Striatal Neurons through Synaptic Plasticity.
Wieland S; Schindler S; Huber C; Köhr G; Oswald MJ; Kelsch W
J Neurosci; 2015 Jul; 35(27):9946-56. PubMed ID: 26156995
[TBL] [Abstract][Full Text] [Related]
8. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats.
Pollack AE; Yates TM
Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212
[TBL] [Abstract][Full Text] [Related]
9. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.
Gerfen CR; Engber TM; Mahan LC; Susel Z; Chase TN; Monsma FJ; Sibley DR
Science; 1990 Dec; 250(4986):1429-32. PubMed ID: 2147780
[TBL] [Abstract][Full Text] [Related]
10. Effects of single and multiple treatments with L-dihydroxyphenylalanine (L-DOPA) on dopamine receptor-G protein interactions and supersensitive immediate early gene responses in striata of rats after reserpine treatment or with unilateral nigrostriatal lesions.
Khan SM; Smith TS; Bennett JP
J Neurosci Res; 1999 Jan; 55(1):71-9. PubMed ID: 9890435
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic treatment weakens medium spiny neuron collateral inhibition in the parkinsonian striatum.
Wei W; Ding S; Zhou FM
J Neurophysiol; 2017 Mar; 117(3):987-999. PubMed ID: 27927785
[TBL] [Abstract][Full Text] [Related]
12. [Paradigm of negative feedback via long-loop in the striatal dopamine release modulation in the rat].
Bueno-Nava A; Gonzalez-Pina R; Avila-Luna A; Alfaro-Rodriguez A
Rev Neurol; 2011 Mar; 52(6):371-7. PubMed ID: 21387254
[TBL] [Abstract][Full Text] [Related]
13. D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons.
Robertson GS; Vincent SR; Fibiger HC
Neuroscience; 1992 Jul; 49(2):285-96. PubMed ID: 1359451
[TBL] [Abstract][Full Text] [Related]
14. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
[TBL] [Abstract][Full Text] [Related]
15. Autoradiographic identification of D1 dopamine receptors labelled with [3H]dopamine: distribution, regulation and relationship to coupling.
Hervé D; Trovero F; Blanc G; Glowinski J; Tassin JP
Neuroscience; 1992; 46(3):687-700. PubMed ID: 1532052
[TBL] [Abstract][Full Text] [Related]
16. Local infusion of the (+/-)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione does not block D1 dopamine receptor-mediated increases in immediate early gene expression in the dopamine-depleted striatum.
Keefe KA; Gerfen CR
Neuroscience; 1999 Mar; 89(2):491-504. PubMed ID: 10077330
[TBL] [Abstract][Full Text] [Related]
17. Dopamine differentially modulates the excitability of striatal neurons of the direct and indirect pathways in lamprey.
Ericsson J; Stephenson-Jones M; Pérez-Fernández J; Robertson B; Silberberg G; Grillner S
J Neurosci; 2013 May; 33(18):8045-54. PubMed ID: 23637194
[TBL] [Abstract][Full Text] [Related]
18. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
[TBL] [Abstract][Full Text] [Related]
19. Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors.
Marti M; Mela F; Bianchi C; Beani L; Morari M
J Neurochem; 2002 Nov; 83(3):635-44. PubMed ID: 12390525
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
Calabresi P; Mercuri NB; Sancesario G; Bernardi G
Brain; 1993 Apr; 116 ( Pt 2)():433-52. PubMed ID: 8096420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
